 TRACON Pharmaceuticals NASDAQ:TCON Inc CEO Charles Theuer said the biopharmaceutical company remains on track to release interim efficacy data from its recently approved amended ENVASARC protocol, using a higher dose of envafolimab, later this year. We are pleased with the pace of enrollment under the amended ENVASARC protocol and remain on track to deliver interim efficacy data in the second half of this year, Theuer said in a statement accompanying the firms 1Q results. 